See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
4BIO Capital is a London-based international venture capital firm focused solely on the advanced therapies sector. The firm's objective is to create, invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to potentially curative therapies for all patients. 4BIO specifically targets viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The team — comprising leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in Nature, The Lancet, Cell, and the New England Journal of Medicine — takes a hands-on, company-building approach, often founding or co-founding portfolio companies from breakthrough academic science.
Notable quotes
“Trogenix perfectly embodies 4BIO's innovation driving playbook, where we support breakthrough biotech companies to develop and deliver exceptional technologies, reach new areas of medicine and pioneer novel treatment possibilities. This investment, supported by an outstanding syndicate of leading investors, demonstrates the value that our hands-on, dedicated approach can have towards transforming innovative concepts into breakthrough therapies.”
“At 4BIO Capital, we strongly believe that advanced therapies and other emerging technologies are the future of healthcare. Our journey through Ventures II brought significant validation to our early-stage creation and incubation strategy, as seen by the upsized and oversubscribed financings of Entact Bio, Code Bio, and Ray Therapeutics as well as the continued success of our existing portfolio.”
“Technical validation could become the primary driver of capital allocation in 2026. Investors will increasingly prioritise credible manufacturability and reproducible performance over compelling narratives alone.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Cytospire Therapeutics | Series A | — | 2026-05-05 |
| Ray Therapeutics | Series B | — | 2026-04-21 |
| Trogenix | Series A | $95m | 2025-10-06 |
| Actithera | Series A | $76m | 2025-07-09 |
| March Biosciences | Series A | — | 2024-10-07 |
| Ascend Gene & Cell Therapies | Series A | $130m | 2023-05-18 |
| Araris Biotech | Seed | $24m | 2022-10-04 |
| Orchard Therapeutics | Series B | — | 2017-12-20 |
| Hornet Therapeutics | Seed | $5m | 2024-05-23 |
| NV Therapeutics | Seed | — | 2025-03-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| IQ Capital | 2 |
| M Ventures | 2 |
| Sofinnova Partners | 2 |
| Syncona Partners | 2 |
| UCL Technology Fund | 2 |
| Abingworth | 2 |
Fit check
Is 4BIO Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit